<DOC>
	<DOCNO>NCT02581345</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , immunogenicity propose adalimumab biosimilar ( M923 ) Humira participant moderate severe chronic plaque-type psoriasis .</brief_summary>
	<brief_title>Phase 3 Study M923 Humira® Subjects With Chronic Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Must able understand communicate investigator comply requirement study 2 . Chronic plaquetype psoriasis diagnose least 6 month screen 3 . Stable plaque psoriasis 4 . History receipt candidate therapy . 5 . Moderate severe psoriasis screen baseline 6 . Must willing able selfadminister SC injection caregiver available administer injection 7 . Male participant childbearing potential must employ highly effective contraceptive measure 8 . Female participant must negative pregnancy test ; plan become pregnant ; must lactate . Female participant must also agree employ highly effective contraceptive measure . 1 . Forms psoriasis chronic plaquetype 2 . Druginduced psoriasis . 3 . Other skin condition would interfere assessment psoriasis 4 . Medical condition psoriasis systemic corticosteroid use last year prior screen 5 . Other inflammatory condition psoriasis psoriatic arthritis 6 . Prior use systemic tumor necrosis factor ( TNF ) inhibitor , 2 nonTNF biologic therapy 7 . Ongoing use prohibit psoriasis treatment 8 . Ongoing use nonpsoriasis prohibit treatment 9 . All prior nonpsoriasis concomitant treatment must stable dose least 4 week 10 . Laboratory abnormality screen deem clinically significant investigator 11 . Any condition illness opinion investigator sponsor pose unacceptable safety risk 12 . History latex allergy 13 . History current sign symptom diagnosis demyelinate disorder 14 . History current Class III IV New York Heart Association congestive heart failure 15 . Signs , symptom , diagnosis lymphoproliferative disorder , lymphoma , leukemia , myeloproliferative disorder , multiple myeloma 16 . Current malignancy history malignancy except adequately treat excised non metastatic basal cell squamous cell cancer skin cervical carcinoma situ ; 3 lifetime basal cell squamous cell carcinoma permit 17 . Chronic infection , recurrent infection ; recent infection evaluate 18 . History presence human immunodeficiency virus ( HIV ) , Hepatitis B ( HBV ) C virus ( HCV ) 19 . History active tuberculosis ( TB ) untreated inadequately treat latent TB . 20 . Exposure investigational product ≤30 day prior enrollment participation another clinical study course study 21 . Participant family member employee investigator site staff study team</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Moderate severe chronic plaque psoriasis</keyword>
	<keyword>Psoriasis</keyword>
</DOC>